Dawnzera — donidalorsen
Named-patient access overview. Dawnzera is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Dawnzera
Dawnzera (donidalorsen) is manufactured by Ionis Pharmaceuticals and indicated for HAE prophylaxis, adult/ped >=12 yrs. It is a approved by the US FDA in 2025 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Dawnzera
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Dawnzera for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Dawnzera is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
We have documented named-patient access pathways for Dawnzera in the countries below. Each page outlines the destination-country regulatory posture, typical timeline, and physician-credential requirements.
Dawnzera in BahrainNamed-patient access, timeline, and regulatory notes
Dawnzera in EgyptNamed-patient access, timeline, and regulatory notes
Dawnzera in IndiaNamed-patient access, timeline, and regulatory notes
Dawnzera in JordanNamed-patient access, timeline, and regulatory notes
Dawnzera in LebanonNamed-patient access, timeline, and regulatory notes
Dawnzera in NepalNamed-patient access, timeline, and regulatory notes
Dawnzera in PakistanNamed-patient access, timeline, and regulatory notes
Dawnzera in QatarNamed-patient access, timeline, and regulatory notes
Dawnzera in Saudi ArabiaNamed-patient access, timeline, and regulatory notes
Start a request for Dawnzera
Submit a 60-second intake. Our clinical team responds within one business day with case-specific feasibility, timeline, and a formal quote.